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ABSTRACT		The	objective	of	this	study	is	to	design	and	evaluate	a	new	EOP	called	swellable	elementary	osmotic	pump	(SEOP)	of	the	freely	water	soluble	drug,	amitriptyline	hydrochloride	(1	g	/mL)	by	adding	water	swellable	polymers	in	the	core.	The	hydrophilic	polymers	included	in	the	core	retard	the	highly	water	soluble	drug	by	producing	hydrogel	within	the	core,	which	may	restrict	and	delay	the	solvent	contact	with	drug	molecules	and	may	increase	the	diffusional	length	of	the	solvent	to	achieve	a	constant	release	rate.	Thus,	this	technol-ogy	can	be	exploited	to	achieve	constant	drug	release	at	predetermined	rate	especially	for	highly	water	sol-uble	drugs.	
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INTRODUCTION	Osmotically	 Controlled	 release	 delivery	 systems	 of	drugs	have	recently	become	an	important	field	of	re-search	because	of	their	extended	and	safe	use.	Among	various	 controlled	 release	 devices,	 osmotically	driven	 system	 hold	 a	 prominent	 place	 because	 of	their	reliability	and	ability	to	devices,	Elementary	os-motic	pumps	(EOPs)	are	the	most	commercially	im-portant	osmotic	devices	because	they	are	easy	to	for-mulate,	 simple	 in	 operation,	 production	 scale	 up	 is	easy	and	most	importantly	releases	the	drug	at	an	ap-
proximate	zero	order	rate.	Drugs	of	extreme	solubil-ity	can	be	formulated	as	osmotically	controlled	sys-tems.	Amitriptyline	hydrochloride,	the	model	drug	is	a	widely	used	 tricyclic	 anti-depressant.	 It	 is	 rapidly	absorbed	from	GI	after	oral	administration	because	of	its	high	solubility[1].		In	 a	 typical	 therapeutic	 regimen	 the	drug	dose	 and	dosing	interval	are	optimized	to	maintain	drug	con-centration	within	 the	 therapeutic	window,	 thus	 en-suring	efficacy	while	minimizing	toxic	effects.	Survey	indicated	 that	dosing	more	 than	one	or	 twice	daily,	greatly	reduces	patient	compliance.	So	in	recent	year	considerable	attention	has	been	focused	on	the	devel-opment	of	novel	drug	delivery	system	and	the	main	reason	for	this	paradigm	shift	is	relatively	low	devel-opment	 cost	 and	 time	 required	 for	 introducing	 a	novel	 drug	 delivery	 system	 as	 compared	 to	 a	 new	chemical	entity[2].	In	the	form	of	novel	drug	delivery	system,	an	existing	drug	molecule	can	get	a	new	life	there	by	increasing	its	market	value	competitiveness	and	patent	life	among	the	various	novel	drug	delivery	system	available	in	the	market,	per	oral	controlled	re-lease	system	hold	the	major	market	share	because	of	their	 obvious	 advantages	 of	 ease	 of	 administration	and	better	patient	compliance.	These	products	pro-vide	significant	benefits	over	immediate	release	for-mulation,	including	greater	effectiveness	in	the	treat-ment	of	chronic	conditions,	reduced	side	effects,	and	greater	patient	convenience	due	to	simplified	dosing	schedule.	
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A	number	of	design	options	are	available	to	control	or	modulate	the	drug	release	from	a	dosage	form.	Major-ity	of	per	oral	dosage	form	fall	in	the	category	of	ma-trix,	 reservoir	or	osmotic	 system.	 In	matrix	 system,	the	drug	is	embedded	in	polymer	matrix	and	the	re-lease	takes	place	by	partitioning	of	drug	into	the	pol-ymer	matrix	and	the	release	medium.	In	contrast,	res-ervoir	systems	have	a	drug	core	surrounded\coated	by	 the	 rate	 controlling	 membrane.	 However	 factor	like	pH,	presence	of	food	and	other	physiological	fac-tor	may	 affect	 drug	 release	 from	 conventional	 con-trolled	release	systems.	Osmotic	systems	utilize	 the	principle	 of	 osmotic	 pressure	 for	 the	 delivery	 of	drugs.	Drug	release	from	these	systems	is	independ-ent	of	pH	and	other	physiological	parameter	to	a	large	extent	and	it	is	possible	to	modulate	the	release	char-acteristic	 by	 optimizing	 the	 properties	 of	 drug	 and	system[2].	 The	 oral	 osmotic	 pumps	 have	 certainly	came	a	 long	way	and	the	available	products	on	this	technology	and	number	of	patent	granted	in	the	last	few	years	makes	it	presence	felt	in	the	market[3].	They	are	also	known	as	gastro	 intestinal	 therapeutic	sys-tem.	Alza	corporation	of	the	USA	was	first	to	develop	an	 oral	 osmotic	 pump	 and	 today	 also	 they	 are	 the	leaders	in	this	field	with	a	technology	named	OROS.	Osmotic	drug	delivery	has	come	long	way	since	Aus-tralian	 pharmacologist	 Rose	 and	 Nelson	 developed	an	implantable	osmotic	pump	in	1955.	Next	quantum	leap	 in	 osmotic	 dosage	 form	 came	 in1972	 when	Theuwes[12]	invented	elementary	osmotic	pump.	Af-ter	 that	many	 of	 have	 been	 invented	which	 enable	controlled	delivery	of	almost	all	drugs.		Controlled	release	dosage	forms	are	designed	to	re-lease	drug	in-vivo	according	to	predictable	rate	that	can	 be	 verified	 by	 in-vitro	 measurement.	 Potential	development	and	new	approaches	to	oral	controlled	release	dosage	form	includes,		1.	Hydrodynamic	pressure	controlled	system	2.	Intragastric	floating	tablet	 	3.	Transmucosal	tablet	4.	Microporous	membrane	coated	tablet	
Advantages	of	osmotic	drug	delivery	system	
• Easy	to	formulate	and	simple	in	operations	
• Improve	 patients	 compliance	 with	 reduce	 fre-quency.		
• Prolong	 therapeutic	 effect	 with	 uniform	 blood	concentration	
• They	typically	give	Zero	order	release	profile	af-ter	an	initial	lag.	
• Deliveries	may	be	delayed	or	pulsed,	if	desired.	
• Drug	 release	 is	 independent	 of	 gastric	 PH	 and	Hydrodynamic	condition.	
• They	are	well	characterized	and	understood.	
• The	release	mechanisms	are	not	dependent	on	drug	
• A	high	degree	of	in-vitro	and	in-vivo	co	relation	(IVIVC)	is	obtained	in	Osmotic	systems	
• The	rationale	for	the	approach	is	that	the	pres-ence	 of	 water	 in	 GIT	 is	 relatively	 constant,	 at	least	 in	 terms	 amount	 required	 for	 activation	and	controlling	osmotically	base	technologies.	
• Higher	 release	 rates	 are	 possible	 for	 Osmotic	systems	compared	with	conventional	diffusion-controlled	drug	delivery	systems	
• The	release	from	Osmotic	systems	is	minimally	effects	by	the	presence	of	food	in	Gastrointesti-nal	tract.	
• The	 release	 rate	 of	 Osmotic	 systems	 is	 highly	predictable	and	can	be	programmed	by	modu-lating	the	release	control	parameters.	
Disadvantages	of	osmotic	drug	delivery	system	
• Toxicity	due	to	Dose	dumping.	
• Rapid	development	of	tolerance.	
• Re-trieval	therapy	is	not	possible	in	the	case	un-expected	adverse	events.	
• Expensive.	
• If	the	coating	process	is	not	well	controlled	there	is	 a	 risk	 of	 slip	 defects,	 which	 results	 in	 dose	dumping.	
• Size	whole	is	critical.	
• Additional	 patient	 education	 and	 counseling	 is	required.	
• Hypersensitivity	 reaction	 may	 occur	 after	 im-plantation.	
Applications	of	odds	Theeuwes	 et	 al	 (1985)	 developed	 elementary	 os-motic	pump	for	metoprolol	and	oxprenolol	for	once	daily	 administration.	 For	 the	desired	 solubility	 suc-cinate	 salt	 of	 oxprenolol	 and	 fumarate	 salt	 of	metoprolol	were	used	along	with	sodium	bicarbonate	as	 osmotic	 agent.	 Highly	 efficient	 method	 of	 laser	drilling	was	used	with	rate	of	failure	less	than	one	in	million.	 The	 systems	were	 found	 to	 be	 stable	 after	storage	 period	 of	 2,	 1,	 and	 1	 years	 at	 23°,	 37°	 and	51°C,	 respectively.	 In	 vitro	 release	 study	 was	 con-ducted	 using	 differential	 method	 apparatus,	 which	indicated	substantial	drug	delivery	(60%)	at	zero-or-der	rates.		Systemic	&	Site-specific	Administration	These	 tech-nologies	allow	drug	delivery	for	site-specific	as	well	as	systemic	use	for	delivery	periods	of	days	to	1	year.	To	deliver	drug	systemically,	the	DUROS®	system	is	placed	just	under	the	skin	e.g.,	in	the	upper	arm,	in	an	out-patient	procedure	that	is	completed	in	just	a	few	minutes	using	 local	anesthetic.	Removal	or	 replace-ment	of	the	product	is	also	a	simple	and	quick	proce-dure	completed	in	doctor's	office.	To	deliver	a	drug	to	a	 specific	 site,	 DURECT	 is	 a	 developing	 proprietary	miniaturized	catheter	technology.	Catheter	can	be	at-tached	to	a	DUROS®	system	to	direct	the	flow	of	drug	
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to	the	target	organ,	tissue	or	synthetic	medical	struc-ture	such	as	a	graft	
ALZET	 osmotic	 pumps	 are	 miniature,	 implantable	pumps	used	for	research	in	mice,	rats,	and	other	la-boratory	animals.	ALZET	pumps	can	be	used	for	sys-temic	 administration	 when	 implanted	 subcutane-ously	or	 intraperitoneally.	ALZET	pumps	have	been	used	 successfully	 to	 deliver	 hundreds	 of	 different	compounds	 including	 antibodies,	 chemotherapeutic	drugs,	cytokines,	growth	factors,	hormones,	and	pep-tides.		liquid	oral	osmotic	system	(l-oros):	To	deliver	drugs	as	liquid	formulations	and	combine	the	benefits	of	ex-tended	release	with	high	bioavailability.	Suitable	for	controlled	delivery	of	lipophilic	drugs.	
Types	of	osmotic	pumps	
 
Figure 1: Classification of Osmotic Pumps	
Rose-Nelson	Pump	Rose	and	Nelson,	the	Australian	scientists,	were	initi-ators	of	osmotic	drug	delivery.	 In	1955,	 they	devel-oped	an	implantable	pump	for	the	delivery	of	drugs	to	the	sheep	and	cattle	gut.		The	Rose-Nelson	 implantable	 pump	is	 composed	 of	three	chambers:	a	drug	chamber,	a	salt	chamber	hold-ing	solid	salt,	and	a	water	chamber.	A	semi	permeable	membrane	 separates	 the	 salt	 from	water	 chamber.	The	movement	of	water	from	the	water	chamber	to-wards	salt	chamber	is	influenced	by	difference	in	os-motic	 pressure	 across	 the	 membrane.	 Conceivably,	volume	of	salt	chamber	increases	due	to	water	flow,	which	distends	the	latex	diaphragm	dividing	the	salt	and	drug	chambers:	eventually,	the	drug	is	pumped	out	of	the	device.	
 
Figure 2: Rose-Nelson Pump	The	kinetics	of	pumping	 from	Rose	Nelson	pump	 is	given	by	the	following	equation:	
	Where	dMt/dt	is	 the	 drug	 release	 rate,	dV/dt	is	 the	volume	flow	of	water	into	the	salt	chamber,	and	Crep-resents	the	concentration	of	drug	in	the	drug	cham-ber.	
	where,	A	is	 the	 area	 of	 semi	 permeable	membrane,	Δπ	is	the	osmotic	pressure	gradient,	θ	is	the	permea-bility	of	semi	permeable	membrane,	and	l	is	the	thick-ness	of	semi	permeable	membrane.	These	basic	equa-tions	 are	 applicable	 to	 the	 osmotically	 driven	 con-trolled	drug	delivery	devices.	The	saturated	salt	solu-tion	 created	 a	 high	 osmotic	 pressure	 compared	 to	that	pressure	required	for	pumping	the	suspension	of	active	 agent.	 Therefore,	 the	 rate	 of	 water	 entering	into	the	salt	chamber	remains	constant	as	long	as	suf-ficient	 solid	 salt	 is	 present	 in	 die	 salt	 chamber	 to	maintain	a	saturated	solution	and	thereby	a	constant	osmotic	pressure	driving	force	is	generated.	The	 major	 problem	 associated	 with	 Rose-Nelson	pumps	was	that	the	osmotic	action	began	whenever	water	came	in	contact	with	the	semi	permeable	mem-brane.	 This	 needed	 pumps	 to	 be	 stored	 empty	 and	water	to	be	loaded	prior	to	use.	
Higuchi-Leeper	Osmotic	Pump	Higuchi	and	Leeper	have	proposed	a	number	of	vari-ations	 of	 the	 Rose-Nelson	 pump	 and	 these	 designs	have	been	described	in	US	patents,	which	represent	the	first	series	of	simplifications	of	the	Rose-Nelson	pump	made	by	the	Alza	Corporation.		
 
Figure 3: Higuchi-Leeper Osmotic Pump	
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The	Higuchi-Leeper	pump	has	no	water	chamber,	and	the	activation	of	the	device	occurs	after	imbibition	of	the	water	 from	 the	 surrounding	 environment.	 This	variation	 allows	 the	 device	 to	 be	 prepared	 loaded	with	drug	and	can	be	stored	for	long	prior	to	use.	Hi-guchi-Leeper	 pumps	 contain	 a	 rigid	 housing	 and	 a	semi	 permeable	 membrane	 supported	 on	 a	 perfo-rated	 frame;	a	salt	chamber	containing	a	 fluid	solu-tion	with	an	excess	of	solid	salt	is	usually	present	in	this	 type	 of	 pump.	 Upon	 administration/implanta-tion,	surrounding	biological	fluid	penetrates	into	the	device	 through	 porous	 and	 semi	 permeable	 mem-brane	 and	 dissolves	 the	 MgSO4,	 creating	 osmotic	pressure	inside	the	device	that	pushes	movable	sepa-rator	toward	the	drug	chamber	to	remove	drug	out-side	the	device.	It	is	widely	employed	for	veterinary	use.	This	type	of	pump	is	implanted	in	body	of	an	an-imal	 for	delivery	of	antibiotics	or	growth	hormones	to	animals.	Pulsatile	delivery	could	be	achieved	by	using	Higuchi	Leeper	 pump.	 The	 Pulsatile	 release	 of	 drug	 is	achieved	by	drilling	the	orifice	in	elastic	material	that	stretches	under	 the	osmotic	pressure.	Pulse	release	of	 drug	 is	 obtained	 after	 attaining	 a	 certain	 critical	pressure,	which	causes	the	orifice	to	open.	The	pres-sure	then	reduces	to	cause	orifice	closing	and	the	cy-cle	 repeats	 to	 provide	 drug	 delivery	 in	 a	 pulsatile	fashion.	The	orifice	should	be	small	enough	to	be	sub-stantially	closed	when	the	threshold	level	of	osmotic	pressure	is	not	present.	
Higuchi-Theeuwes	Osmotic	Pump	Higuchi	and	Theeuwes	in	early	1970s	developed	an-other	variant	of	the	Rose-Nelson	pump,	even	simpler	than	the	Higuchi-Leeper	pump.		
 
 
 
Figure 4: Higuchi-Theeuwes Osmotic Pump 
In	 this	device,	 the	rigid	housing	consisted	of	a	semi	permeable	 membrane.	 This	 membrane	 is	 strong	enough	 to	 withstand	 the	 pumping	 pressure	 devel-oped	inside	the	device	due	to	imbibition	of	water.	The	drug	is	loaded	in	the	device	only	prior	to	its	applica-tion,	which	extends	advantage	for	storage	of	the	de-vice	for	longer	duration.	The	release	of	the	drug	from	the	 device	 is	 governed	 by	 the	 salt	 used	 in	 the	 salt	chamber	and	the	permeability	characteristics	of	the	outer	membrane.	Small	osmotic	pumps	of	this	form	are	available	under	trade	name	Alzet	made	by	Alza	Corporation	in	1976.	They	 are	used	 frequently	 as	 implantable	 controlled	release	delivery	systems	in	experimental	studies	re-quiring	continuous	administration	of	drugs.		
Elementary	osmotic	pump	(EOP)	Rose-Nelson	pump	was	further	simplified	in	the	form	of	 elementary	 osmotic	 pump,	 which	 made	 osmotic	delivery	 as	 a	major	method	 of	 achieving	 controlled	drug	 release.	 Elementary	 osmotic	 pump	 shown	in	was	 invented	by	Theeuwes	 in	1974	and	 it	essen-tially	 contains	 an	 active	 agent	having	 a	 suitable	os-motic	pressure;	it	is	fabricated	as	a	tablet	coated	with	semi	permeable	membrane,	usually	cellulose	acetate.	A	small	orifice	is	drilled	through	the	membrane	coat-ing.	When	this	coated	tablet	is	exposed	to	an	aqueous	environment,	 the	 osmotic	 pressure	 of	 the	 soluble	drug	inside	the	tablet	draws	water	through	the	semi	permeable	coating	and	a	saturated	aqueous	solution	of	drug	is	formed	inside	the	device.	The	membrane	is	nonextensible	and	the	increase	in	volume	due	to	im-bibition	of	water	raises	the	hydrostatic	pressure	in-side	the	tablet,	eventually	leading	to	flow	of	saturated	solution	of	active	agent	out	of	 the	device	 through	a	small	orifice.		The	pump	initially	releases	the	drug	at	a	rate	given	by	the	following	equation;	
	where	dV/dt	depicts	 the	 water	 flow	 into	 the	 tablet	and	Cs	is	the	solubility	of	the	agent	inside	the	tablet.	
Push-Pull	Osmotic	Pump	(PPOP)	Push-pull	 osmotic	 pump	 is	 a	 modification	 of	 EOP.	Push-pull	osmotic	pump	is	delivered	both	poorly	wa-ter	soluble	and	highly	water	soluble	drugs	at	a	con-stant	rate.	This	system	resembles	a	standard	bilayer	coated	 tablet.	 One	 layer	 (the	 upper	 layer)	 contains	drug	 in	 a	 formulation	 of	 polymeric,	 osmotic	 agent,	and	other	 tablet	 excipients.	This	polymeric	osmotic	agent	has	the	ability	to	form	a	suspension	of	drug	in	situ.	When	this	tablet	later	imbibes	water,	the	other	layer	contains	osmotic	and	colouring	agents,	polymer	and	 tablet	 excipients.	 These	 layers	 are	 formed	 and	bonded	together	by	tablet	compression	to	form	a	sin-gle	bilayer	core.	The	tablet	core	 is	then	coated	with	semi	 permeable	 membrane.	 After	 the	 coating	 has	
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been	applied,	a	small	hole	is	drilled	through	the	mem-brane	by	a	laser	or	mechanical	drill	on	the	drug	layer	side	of	the	tablet.	When	the	system	is	placed	in	aque-ous	environment,	water	is	attracted	into	the	tablet	by	an	osmotic	agent	in	both	the	layers.	The	osmotic	at-traction	 in	 the	drug	 layer	pulls	water	 into	 the	com-partment	to	form	in	situ	a	suspension	of	drug.	The	os-motic	agent	in	the	nondrug	layer	simultaneously	at-tracts	water	into	that	compartment,	causing	it	to	ex-pand	 volumetrically,	 and	 the	 expansion	 of	 nondrug	layer	pushes	the	drug	suspension	out	of	the	delivery	orifice.		
 
Figure 5: The push-pull osmotic pump (PPOP)	
Controlled	Porosity	Osmotic	Pump	(CPOP)	It	 is	an	osmotic	 tablet	wherein	 the	delivery	orifices	(holes)	are	formed	in	situ	through	leaching	of	water	soluble	 pore-forming	 agents	 incorporated	 in	 semi-permeable	 membrane	 (SPM)	 (e.g.,	 urea,	 nicotina-mide,	sorbitol,	etc.).	Drug	release	rate	from	CPOP	de-pends	on	various	factors	like	coating	thickness,	solu-bility	of	drug	 in	 tablet	core,	 level	of	 leachable	pore-forming	agent(s)	and	the	osmotic	pressure	difference	across	the	membrane.		Mechanism	of	action	of	 controlled	porosity	osmotic	pump.	There	are	several	obvious	advantages	inherent	to	the	CPOP	 system.	 The	 stomach	 irritation	 problems	 are	considerably	 reduced,	 as	 drug	 is	 released	 from	 the	whole	of	the	device	surface	rather	from	a	single	hole.	Further,	no	complicated	laser-drilling	unit	is	required	because	 the	 holes	 are	 formed	in	 situ.	 Scheme	 de-scribes	the	drug	release	phenomenon	from	a	typical	CPOP	.	
Liquid-Oral	Osmotic	(L-OROS)	System	Various	 L-OROS	 systems	 available	 to	 provide	 con-trolled	delivery	of	liquid	drug	formulations	include	L-OROS	hardcap,	L-OROS	softcap,	and	a	delayed	liquid	bolus	delivery	system.	Each	of	these	systems	includes	a	liquid	drug	layer,	an	osmotic	engine	or	push	layer,	and	a	semi	permeable	membrane	coating.	When	the	system	is	 in	contact	with	the	aqueous	environment,	water	 permeates	 across	 the	 rate-controlling	 mem-brane	and	activates	the	osmotic	layer.		The	expansion	of	the	osmotic	layer	results	in	the	de-velopment	of	hydrostatic	pressure	inside	the	system,	thereby	forcing	the	liquid	formulation	to	be	delivered	at	the	delivery	orifice.	Whereas	L-OROS	hardcap	and	
L-OROS	softcap	systems	are	designed	to	provide	con-tinuous	drug	delivery,	the	L-OROS	delayed	liquid	bo-lus	delivery	system	is	designed	to	deliver	a	pulse	of	liquid	drug.	
 
Figure 6: Liquid oral osmotic pump	
Liquid	oral	osmotic	pump.	The	delayed	liquid	bolus	delivery	system	comprises	three	layers:	a	placebo	delay	layer,	a	liquid	drug	layer,	and	an	osmotic	engine,	all	surrounded	by	a	rate-con-trolling	semi	permeable	membrane	(SPM).	The	deliv-ery	orifice	is	drilled	on	the	placebo	layer	end	of	the	capsule	shaped	device.	When	the	osmotic	engine	ex-pands,	the	placebo	is	released	first,	delaying	release	of	the	drug	layer	Drug	release	can	be	delayed	from	1	to	10	hours,	depending	on	permeability	of	the	rate-controlling	membrane	and	the	size	of	placebo		
Sandwiched	Osmotic	Tablet	(SOT)	This	 shows	 that	 sandwiched	osmotic	 tablet	 is	 com-posed	of	polymeric	push	layer	sandwiched	between	two	 drug	 layers	 with	 two	 delivery	 orifices.	 When	placed	in	the	aqueous	environment,	the	middle	push	layer	containing	the	swelling	agents'	swells	and	the	drug	is	released	from	the	two	orifices	situated	on	op-posite	 sides	of	 the	 tablet;	 thus	 sandwiched	osmotic	tablets	 (SOTS)	 can	 be	 suitable	 for	 drugs	 prone	 to	cause	local	irritation	of	the	gastric	mucosa.	
Mechanism	of	osmosis	Core	contain	water	soluble	osmotically	active	agent	and	blended	with	water	soluble	or	insoluble	drug,	ad-ditives	and	coating	has	been	carried	out	which	func-tions	as	semi	permeable	membrane.		Since	barrier	is	only	permeable	to	water,	initial	pene-tration	of	water	dissolves	the	critical	part	of	the	core,	resulting	in	development	of	an	osmotic	pressure	dif-ference	across	the	membrane.	The	device	delivers	a	saturated	volume	equal	to	the	volume	of	water	uptake	through	the	membrane.	Ini-tial	lag	time	(per	hour)	during	which	delivery	rate	in-creases	to	its	maximum	value,	drug	release	is	zero	or-der,	until	all	solid	material	is	dissolved.	
Osmotic	system	theory	Osmotic	system	release	a	therapeutic	agent	at	a	pre-determined,	typically	zero	order	delivery	rater	based	on	the	principle	of	osmosis.	Osmotic	system	imbibe	
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water	from	the	body	through	a	semipermiable	mem-brane	in	to	an	osmotic	materials,	which	swell	result-ing	in	slow	and	even	delivery	of	drug	formulations.	
MATERIALS	AND	METHODS	
Components	of	dosage	form	
• Drug	
• Semipermeable	membrane	
• Osmogen	 /	 osmogent	 /	 osmotic	 driving	agent	
• Hydrophilic	and	hydrobhobic	polymers	
• Wicking	agents  
• Solubilizing	agents	
• Surfactants	
• Coating	solvents	
• Plasticizers	
• Flux	regulators	
• Pore	forming	agents	
Method	of	preparation	(by	wet	granulation):	Mix	 drug,	 lactose	 sodium	 carboxy	 methyl	 cellulose	and	PVP	K30	in	mortar	and	pestle.	Mix	it	and	prepare	a	 dough.	 Keep	 the	 dough	 in	 an	 autoclave	 and	 then	make	granules	by	passing	through	seive	no.	20.	Allow	the	granules	to	dry	by	keeping	them	in	oven	at	400C	for	20	minutes.	Add	magnesium	stearate,	talc,	manni-tol	to	the	granules.	Now	compress	the	granules	by	us-ing	tablet	compression	machine,	The	size	of	the	dye	was	3x5mm.	
Coating:	Ingredients:	Guar	gum	-	1	gm	Cellulose	acetate	-	5gm	Poly	vinyl	pyrrolidine	-	250mg	Propane-2-one(solvent)	
Preparation	of	coating	solution:	Mix	the	above	 ingredients	(guar	gum,	cellulose	ace-tate,	PVP)	in	a	mortor	and	pestle.		Now	slowly	add	the	solvent	along	with	continuous	stirring	until	a	homog-enous	slurry	is	obtained.	
Coating	procedure	Coating	in	done	by	using	pan	coating	machine.	First	the	coating	solution	is	filled	in	the	sprayer.	Now	the	tablets	are	placed	in	the	coating	pan,	and	are	allowed	to	 rotate	 at	 70-100	 rpm	 and	 temperature	 is	 main-tained	at	500C,	by	passing	hot	air.	After	the	coating	is	completed	the	tablets	are	collected	and	packed	
Factors	affecting	release	of	medicament	Factors	affecting	the	release	rate	of	medicament	from	osmotic	drug	delivery	system	are,	1.	Solubility	2.	Osmotic	pressure	
3.	Delivery	orifice	4.	Membrane	type	
Solubility	Solubility	of	drug	is	one	of	the	most	important	factors	since	kinetic	of	osmotic	release	is	directly	related	to	the	drug	solubility.	The	fraction	of	a	drug	release	with	zero	order	kinetic	is	given	by,	F	(z)	=	1	–	S	/	Р	Where	F	(z)	=	fraction	release	by	zero	order	S	=	drug	solubility	in	g	/	cm	3	P	=	density	of	core	tablet.	Drug	with	 density	 of	 unity	 and	 solubility	 less	 than	0.05	g	/	cm	3	would	release	greater	than	or	equals	to	95	%	by	zero	order	kinetics	Drug	 with	 density	 >	 0.3	 g	 /	 cm	 3	 solubility	 would	demonstrate	with	higher	release	rate	>	70	%	by	zero	order.	
Solubility-modifying	approaches;	Use	 of	 swellable	 polymer	 vinyl	 acetate	 copolymer,	polyethylene	oxide	have	uniform	swelling	rate	which	causes	drug	releases	at	constant	rate.	Use	of	wicking	agents:	These	agents	may	enhance	the	surface	area	of	drug	with	the	incoming	aqueous	flu-ids.	eg:	colloidal	silicon	dioxide,	sodium	lauryl	sulphate,	etc	Ensotrol	 technology	 uses	 the	 same	 principle	 to	 de-liver	drugs	via	osmotic	mechanism.	Use	 of	 effervescent	mixtures,	 mixture	 of	 citric	 acid	and	 sodium	 bicarbonate	 which	 creates	 pressure	 in	the	 osmotic	 system	 and	 ultimately	 controls	 the	 re-lease	rate.	
Osmotic	pressure	Rate	 of	 drug	 release	 from	an	Osmotic	 system	 is	 di-rectly	proportional	 to	Osmotic	Pressure	of	 the	 core	formulation,	EQN	In	order	to	achieve	optimized	and	constant	Osmotic	Pressure	 in	 compartment	 Osmotic	 agent	 must	 be	added	to	tablet.	So	varying	 the	osmogen	vary	osmotic	pressure	and	hence	drug	 release.	Osmogen	are	 classified	as	 inor-ganic	and	organic	osmogens	
Delivery	orifice	
Ø Laser,	
Ø Microdrill,	
Ø Modified	punches,	
Ø Controlled	 porosity	 osmotic	 pumps	 can	 be	generated	 by	 in-situ	 formation	 of	 delivery	
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orifice	which	 has	 been	described	 in	US	Pa-tent.	In	case	of	Propranalol	HCL	Oral	Osmotic	Tablet,	1.	 Tablet	 with	 orifice	 diameter	 of	 200	 –	 800	 μm	showed	zero	order	release	and	2.	The	same	with	1	mm	orifice	diameter	showed	ab-normal	release.	So	infact	orifice	diameter	should	be	below	Amax	and	should	be	greater	than	Amin	since	in	vivo	drug	tablet	will	swell	and	still	minimize	the	bore.	So	uneven	and	unpredictible	release	will	occur.	For	 delivery	 containing	 KCl,	 orifice	 should	 be	 be-tween	75	to	275	microns	in	diameter	
Membrane	type	Drug	 release	 from	 osmotic	 system	 is	 largely	 inde-pendent	of	pH	and	agitational	intensity	of	GIT	Examples	 are	 Cellulose	 Ester,	 Cellulose	 Triacetate,	Cellulose	Propionate,	Cellulose	Acetate	Butyrate,	Es-ter,	Ethyl	Cellulose	and	Eudragits.	Among	above	Cellulose	Acetate	Butyrate	is	most	com-monly	used	since	of	its,	1.	High	water	permeability,	2.	Permeability	can	be	adjusted	by	varying	the	degree	of	acetylation	of	polymer	and	also	by	increasing	plas-tisizer	concentration,	3.	Flux	enhancer	and,	4.	 Superior	 drying	 property	 so	 advantageneous	 to	thermolabile	drugs.	However	 asymmetric	 membrane	 capsule	 are	 new	type	of	coating	which	can	be	fully	utilized	for	osmotic	drug	delivery	system	and	offers	significant	advantage	over	 membrane	 coating	 used	 in	 conventional	 Os-motic	DDS	which	devoid	of	coating	defects	and	they	are	having	higher	rate	of	water	influx	which	allow	the	release	of	drug	with	lower	or	no	osmotic	pressure	or	lower	solubility.	
Evaluation	of	osmotic	drug	delivery	system	
hardness:	 It	 is	 tested	 mainly	 by	 using	 Monsanto-hardness	tester.	
friability:	It	is	mainly	tested	by	using	Roche	friabrila-tor.	
Disintegration	 time:	 It	 was	 determined	 by	 using	thermionic	 tablet	 disintegration	 test	machine	 using	water	as	test	fluid.	
Dissolution:	Dissolution	rate	studies	was	studied	in	phosphate	buffer	of	Ph-6.8	by	using	8	station	dissolu-tion	apparatus	with	paddle	as	a	stirrer	at	50RPM	at	a	temperature	of	37+	10C	was	maintained	throughout	the	study.	1	 tablet	of	4omg	of	valsartan	was	used	 in	each	 test	samples	of	dissolution	media	(5ml)	were	withdrawn	
through	a	 filter	 (0.45	micron)	pore	size	at	different	intervals	 of	 time	 suitably	 diluted	 and	 assayed	 at	225nm	for	valsartan.	The	samples	of	dissolution	fluid	were	replaced	with	fresh	 fluid.	 The	 dissolution	 experiment	 were	 repli-cated	3	times	each	(N=	3).	
Formulation	and	methodology		
Table 1: Ingredients (for 40 tablets) 
Sl.NO	 Ingredients	 Quantity	1	 Drug	 40mg	2	 Lactose	 60mg	3	 Sodium	carboxy	methyl		cellulose	 10mg	4	 PVP	K30	in	hot	water	 10mg	5	 Starch	insoluble	 25mg	6	 Magnesium	stearate	 10mg	7	 Talc	 10mg	8	 Mannitol	(10%)	 15mg	
Invitro	evaluation	The	in	vitro	release	of	drugs	from	oral	osmotic	sys-tems	 has	 been	 evaluated	 by	 the	 conventional	 USP	paddle	and	basket	type	apparatus.	The	dissolution	medium	 is	generally	distilled	water	as	well	as	simulated	gastric	fluid	(for	first	2-4	h)	and	intestinal	 fluids	 (for	 subsequent	 hours)	 have	 been	used.	The	 standard	 specifications,	which	 are	 followed	 for	the	oral	controlled	drug	delivery	systems	are	equiva-lently	applicable	for	oral	osmotic	pumps.	In	vivo	evaluation	of	oral	osmotic	systems	has	been	carried	out	mostly	in	dogs.	Monkeys	can	also	be	used	but	in	most	of	the	studies	the	dogs	are	preferred.	
In	vivo	evaluation	This	evaluation	has	been	usually	camed	out	in	dogs,		moneys	can	also	be	used.	But	in	most	cases	dogs	are	preferred.	Osmotic	 were	 evaluated	 for	 following	 parameters	namely	
• Physical	appearance	
• Dimensions	
• Hardness	
• Friability	
• Invitro	dmg	release	
• Type	of	polymer	used	
• Concentration	of	polymer	
• Concentration	of	osmo	agent	
• PH	modulating	agent	on	release	rate.	Grarimetric	erosion	studies	were	also	performed	 in	some	selected	formulations.	Influence	of	dissolution	medium,	osmotic	P,	and	agitation	on	dmg	release	was	also	investigated	
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Future	brands	Drug	delivery	in	general	will	continue	to	see	signifi-cant	growth	in	the	pharmaceutical	industry	corpora-tion	of	dmg	delivery	concepts	such	as	bioavailability	enhasment	and	controlled	release	in	to	the	develop-ment	 of	 new	 chemical	 entilies	 (NCE)	 is	 the	 logical	steps.	
Products	 Incorporating	ALZA's	OROS®	Technol-
ogy			Alpress™	LP	(prazosin)	once-daily	extended-release	tablet	sold	 in	France	 for	 the	treatment	of	hyperten-sion.	Cardura®	XL	(doxazosin	mesylate)	sold	in	Ger-many	for	the	treatment	of	hypertension.	 	Concerta®	(methylphenidate	HCl)	 CII	 once-daily	 extended-	 re-lease	tablet	for	the	treatment	of	Attention	Deficit	Hy-peractivity	Disorder	(ADHD)	in	patients	age	six	and	older.	Covera-HS®	(verapamil)	a	Controlled	Onset	Ex-tended	Release	(COER-24™)	system	for	the	manage-ment	of	hypertension	and	angina	pectoris.		Ditropan	XL®	 (oxybutynin	 chloride)	 extended-release	 tablet	for	 the	 once-a-day	 treatment	 of	 overactive	 bladder	characterized	by	symptoms	of	urge	urinary	 inconti-nence,	 urgency	 and	 frequency.	 DynaCirc	 CR®	 (is-radipine)	once-daily,	Extended-release	tablet	for	the	treatment	of	hypertension.	Efidac	24®	(chlorphenira-mine)	 over-the-counter,	 extended-release	 tablet	providing	24-hour	relief	from	allergy	symptoms	and	nasal	congestion.	Glucotrol	XL®	(glipizide)	extended-release	tablet	used	as	an	adjunct	to	diet	for	the	con-trol	of	hyperglycemia	in	patients	with	non-insulin-de-pendent	diabetes.	Sudafed®	24	Hour	(pseudoephed-rine)	 over-the-counter	 nasal	 decongestant	 for	 24-hour	relief	of	colds,	sinusitis,	hay	fever	and	other	res-piratory	 allergies.	 Procardia	 XL®	 (nifedipine)	 ex-tended-release	tablet	for	the	treatment	of	angina	and	hypertension.	Volmax®	(albuterol)	extended-release	tablet	for	relief	of	bronchospasm	in	patients	with	re-versible	obstructive	airway	disease	
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